Stocks

ADMA Biologics (NASDAQ:ADMA) Stock Price Rises 6.1%: Is It Time to Buy?

Published March 20, 2025

On Wednesday, the stock price of ADMA Biologics, Inc. (NASDAQ:ADMA) saw an increase of 6.1%. During trading, the stock reached a high of $19.91 and was last seen at $19.85. Approximately 2,397,523 shares changed hands throughout the day, marking a 28% decrease from the average daily volume of 3,320,496 shares. The previous closing price was $18.71.

Wall Street Analysts' Insights

Analyst Recommendations

In a recent report issued on March 4th, Cantor Fitzgerald maintained an "overweight" rating on ADMA Biologics and set a price target of $25.00.

ADMA Biologics Financial Metrics

The company currently has a debt-to-equity ratio of 0.48, a quick ratio of 3.26, and a current ratio of 7.09. ADMA Biologics holds a market capitalization of $4.74 billion, a price-to-earnings ratio of 71.57, and a beta of 0.60. Its 50-day moving average price stands at $16.67, while the two-hundred-day moving average price is $17.98.

Institutional Investments

Several institutional investors and hedge funds have made adjustments to their holdings in ADMA Biologics. Natixis Advisors LLC invested approximately $345,000 in a new stake during the third quarter. Mutual of America Capital Management LLC acquired a new position worth about $701,000 in the same time frame. Thrivent Financial for Lutherans purchased a stake valued at approximately $3,802,000, while First Turn Management LLC bought shares for around $13,293,000. Lastly, Aviance Capital Partners LLC invested approximately $229,000 in ADMA Biologics. Currently, institutional investors and hedge funds own 75.68% of the company's stock.

Overview of ADMA Biologics

ADMA Biologics, Inc. focuses on the development, manufacturing, and marketing of specialized plasma-derived biologics. These products are aimed at treating immune deficiencies and infectious diseases both in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product designed for the treatment of primary humoral immunodeficiency (PI), and ASCENIV, another IVIG product for the same condition. Additionally, they provide Nabi-HB, which treats acute exposure to blood containing Hepatitis B surface antigen among other related exposures.

Investment Considerations

Before making any investment decisions regarding ADMA Biologics, it is essential to be aware of other options available in the market. Although ADMA Biologics has received favorable ratings from analysts, there may be other stocks that could represent better investment opportunities at this time.